Dysport

Dysport temporarily treats moderate to severe frown lines between the eyebrows by reducing specific muscle activity.

Wrinkles are caused by repeated movements and muscle contractions.7 One injection into each of the 5 points between and above the eyebrows temporarily prevents muscle contractions that cause frown lines.

For adults who want a natural look, Dysport is a natural-looking, fast-acting1-3, long-lasting1,2,4 prescription injection proven to help smooth moderate to severe frown lines between the eyebrows—without changing the look or movement of the rest of your face.

Dysport is approved in 69 countries5 and has 25 years of clinical experience worldwide.6* Find out why 97% of women treated with Dysport say they’d do it again.

*Includes therapeutic and aesthetic uses.

  • Subject’s satisfaction and self-perception reported 3 weeks after treatment (n=531).
  • Design: Multicenter, prospective, non-interventional observational study conducted in France, Germany, Spain and the United Kingdom (n=533). Subjects were eligible if the investigator had decided to prescribe Dysport according to the labeling. Subjects completed questionnaires at 3 weeks and 4 months after treatment.

Natural-looking. Fast-acting. Long-lasting.

Reference:

  1. Data on file. GL-Y-97-52120-085 (GL-2) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007.
  2. Data on file. GL-Y-97-52120-719 (GL-1) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007.
  3. Data on file. GL-Y-97-52120-718 (GL-3) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007.
  4. Data on file. MA-35497. Post Hoc Analysis. Fort Worth, TX: Galderma Laboratories, L.P., 2017.
  5. Data on file. Ipsen World-Wide Marketing Authorisation Status. Fort Worth, TX: Galderma Laboratories, L.P., February 2017.
  6. Medicines and Healthcare products Regulatory Agency (MHRA). Botulinum Toxin Type A Powder For Solution For Injection (Clostridium botulinum toxin type A – Haemagglutinin complex). http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con108644.pdf. Accessed December 6, 2019.
  7. Molina B, Grangier Y, Mole B, et al. Patient satisfaction after the treatment of glabellar lines with Botulinum toxin type A (Speywood Unit): a multi-centre European observational study. J Eur Acad Dermatol Venereol. 2015;29(7):1382-1388.
  8. Data on file. 43USD1802 Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2020.